Skip to main content
Premium Trial:

Request an Annual Quote

Spanish Dx Firm Imegen Acquired in €10M Private Equity Buyout

NEW YORK (GenomeWeb) – Spanish diagnostics company Imegen has been acquired by private equity investors for €10 million ($10.8 million), according to a European news report which the company has confirmed.

Q-Growth Fund and Biolty bought out 41 of the 42 shareholders in the Valencia, Spain-based firm. The investors are also Spanish firms.

Founded in 2009, Imegen specializes in clinical genetics and genomics, offering tests for more than 1,500 human genetic diseases, including cancer and rare diseases; prenatal diagnostics; reproductive screening; and custom assay development. The firm also offers genomic testing for ag-bio applications through Imegenagro.

Imegen CEO Ángela Pérez said in a statement that the proceeds will help professionalize the firm and provide funding to consolidate its business overseas. She will remain a shareholder and will continue to lead the company.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.